CureVac NV (5CV) - Net Assets
Based on the latest financial reports, CureVac NV (5CV) has net assets worth €871.23 Million EUR (≈ $1.02 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.14 Billion ≈ $1.33 Billion USD) and total liabilities (€267.39 Million ≈ $312.61 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CureVac NV (5CV) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €871.23 Million |
| % of Total Assets | 76.52% |
| Annual Growth Rate | 67.01% |
| 5-Year Change | -2.07% |
| 10-Year Change | N/A |
| Growth Volatility | 95.78 |
CureVac NV - Net Assets Trend (2018–2024)
This chart illustrates how CureVac NV's net assets have evolved over time, based on quarterly financial data. See 5CV cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for CureVac NV (2018–2024)
The table below shows the annual net assets of CureVac NV from 2018 to 2024. For live valuation and market cap data, see 5CV market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €696.61 Million ≈ $814.41 Million |
+34.76% |
| 2023-12-31 | €516.94 Million ≈ $604.36 Million |
-3.06% |
| 2022-12-31 | €533.25 Million ≈ $623.43 Million |
-22.55% |
| 2021-12-31 | €688.48 Million ≈ $804.90 Million |
-3.22% |
| 2020-12-31 | €711.35 Million ≈ $831.64 Million |
+1761.95% |
| 2019-12-31 | €-42.80 Million ≈ $-50.04 Million |
-233.41% |
| 2018-12-31 | €32.08 Million ≈ $37.51 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to CureVac NV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 98772200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €2.10 Billion | 301.52% |
| Total Equity | €696.61 Million | 100.00% |
CureVac NV Competitors by Market Cap
The table below lists competitors of CureVac NV ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Asseco South Eastern Europe S.A.
WAR:ASE
|
$885.49 Million |
|
Vertex
NASDAQ:VERX
|
$885.83 Million |
|
Neurones
PA:NRO
|
$885.97 Million |
|
Sharda Cropchem Limited
NSE:SHARDACROP
|
$886.18 Million |
|
Zhang Jia Jie Tourism Group Co Ltd
SHE:000430
|
$885.01 Million |
|
Wuzhou Special Paper Group Co. Ltd.
SHG:605007
|
$884.80 Million |
|
Jiangsu Olive Sensors High-Tech Co Ltd
SHE:300507
|
$884.56 Million |
|
Cementos Pacasmayo SAA ADR
NYSE:CPAC
|
$884.47 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CureVac NV's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 516,941,000 to 696,608,000, a change of 179,667,000 (34.8%).
- Net income of 162,186,000 contributed positively to equity growth.
- Other factors increased equity by 17,481,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €162.19 Million | +23.28% |
| Other Changes | €17.48 Million | +2.51% |
| Total Change | €- | 34.76% |
Book Value vs Market Value Analysis
This analysis compares CureVac NV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.26x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 21.48x to 1.26x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | €0.18 | €3.91 | x |
| 2019-12-31 | €-0.24 | €3.91 | x |
| 2020-12-31 | €3.94 | €3.91 | x |
| 2021-12-31 | €3.68 | €3.91 | x |
| 2022-12-31 | €2.74 | €3.91 | x |
| 2023-12-31 | €2.31 | €3.91 | x |
| 2024-12-31 | €3.11 | €3.91 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CureVac NV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 23.28%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 30.30%
- • Asset Turnover: 0.67x
- • Equity Multiplier: 1.15x
- Recent ROE (23.28%) is above the historical average (-53.41%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -222.05% | -553.50% | 0.10x | 3.92x | €-74.45 Million |
| 2019 | 0.00% | -573.46% | 0.13x | 0.00x | €-95.59 Million |
| 2020 | -18.25% | -265.44% | 0.03x | 2.12x | €-200.93 Million |
| 2021 | -59.80% | -399.76% | 0.09x | 1.68x | €-480.56 Million |
| 2022 | -46.70% | -369.37% | 0.08x | 1.61x | €-302.35 Million |
| 2023 | -50.33% | -483.96% | 0.07x | 1.52x | €-311.86 Million |
| 2024 | 23.28% | 30.30% | 0.67x | 1.15x | €92.53 Million |
Industry Comparison
This section compares CureVac NV's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,435,678,106
- Average return on equity (ROE) among peers: -30.54%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CureVac NV (5CV) | €871.23 Million | -222.05% | 0.31x | $885.32 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $66.68 Million | -96.62% | 1.57x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $5.54 Million | -319.56% | 1.20x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $441.80 Million | 197.40% | 0.37x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $230.94 Million | -20.03% | 0.13x | $179.82 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $1.05 Billion | -15.51% | 0.36x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $1.10 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.60 Million | -113.13% | 0.23x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $715.50 Million | -24.53% | 0.64x | $1.82 Billion |
| BioNTech SE (22UA) | $11.89 Billion | 86.54% | 0.33x | $20.05 Billion |
About CureVac NV
As of December 18, 2025, CureVac N.V. was acquired by BioNTech SE. CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRN… Read more